Inari Medical to Announce First Quarter 2022 Financial Results
Inari Medical, Inc. (NASDAQ: NARI) will release its Q1 2022 financial results on May 4, 2022. The company aims to transform the treatment of venous diseases with innovative catheter-based thrombectomy devices. Inari's ClotTriever is FDA 510(k)-cleared for deep vein thrombosis treatment, while FlowTriever is cleared for pulmonary embolism. Following the earnings release, a conference call will be held to discuss financial results and updates. Interested parties can access the live call and webinar via the company's investor relations website.
- Inari's ClotTriever and FlowTriever devices are 510(k)-cleared by the FDA, indicating regulatory approval.
- The company is focused on addressing venous thromboembolism, a critical area in medical treatment.
- None.
IRVINE, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its first quarter 2022 financial results on Wednesday, May 4, 2022. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
Interested parties may access the live call via telephone by dialing (833)-519-1265 for domestic callers or (914)-800-3838 for international callers, using conference ID: 1854706. The live webinar may be accessed by visiting the Events Section of the Inari investor relations website at ir.inarimedical.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on Inari’s website.
About Inari Medical, Inc.
Inari Medical, Inc. is a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of pulmonary embolism and clot in transit in the right atrium.
Investor Contact:
ICR Westwicke
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com
FAQ
When will Inari Medical release its first quarter 2022 financial results?
What are the products developed by Inari Medical?
How can I access the conference call for Inari Medical's financial results?
What is the purpose of Inari Medical's devices?
